Work

Use of DARPP-32 to increase interactions between EGFR and ERBB3 and to promote gastric cancer resistance to gefitinib.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.4_suppl.18

Authors: Shoumin Zhu, Abbes Belkhiri, Alexander Zaika, Wael El-Rifai

Institution: Vanderbilt University Medical Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2560839768

Cites:

Cited by: 1

Related to: 10